Omthera Pharmaceuticals, Inc. 4
4 · Omthera Pharmaceuticals, Inc. · Filed Jul 18, 2013
Insider Transaction Report
Form 4
Machielse Bernardus N M
Executive VP and COO
Transactions
- Exercise/Conversion
Common Stock
2013-07-16$2.08/sh+221,404$460,520→ 247,005 total - Disposition to Issuer
Common Stock
2013-07-18−247,005→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2013-07-16−221,404→ 0 totalExercise: $2.08Exp: 2021-09-07→ Common Stock (221,404 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Omthera Pharmaceuticals, Inc. (the "Company"), Zeneca, Inc. and KAFA Acquisition Corp., dated May 27, 2013 (the "Merger Agreement"), each share of the Company's common stock was exchanged for $12.70 in cash, without interest, less any applicable withholding taxes, plus one contractual contingent value right, which represents the right to receive contingent payments of up to approximately $4.70 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
- [F2]Pursuant to the Merger Agreement, this stock option has been accelerated and is fully vested.